Martin Auster

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) shares were plunging Wednesday after a negative outcome for a binary event. BioMarin Investors Disappointed By FDA News: The FDA issued a complete response letter to BioMarin's biologic license application for valoctocogene roxaparvovec...

Shares of small-cap biopharma Acceleron Pharma Inc (NASDAQ: XLRN) are advancing to an all-time high Tuesday following a data readout. Primary, Secondary Endpoints Met Acceleron said a Phase 2 study dubbed PULSAR that evaluated its sotatercept in patients with pulmonary arterial hypertension, or PAH...

Sarepta Therapeutics Inc (NASDAQ: SRPT) has entered a partnership with Roche (OTC: RHHBY) to commercialize SRP-9001, its gene therapy for Duchenne Muscular Dystrophy, outside of the U.S. The deal secures Sarepta a $1.15 billion upfront payment — $750 million in cash and $400 million in an...

After an earlier rejection, Sarepta Therapeutics Inc (NASDAQ: SRPT)'s Vyondys 53 received FDA approval the second time around, sending the stock sharply higher Friday. Sarepta Succeeds On Second Try  Cambridge, Massachusetts-based Sarepta said Thursday that the FDA granted...

Sarepta Therapeutics Inc (NASDAQ: SRPT)'s new drug application for its second Duchenne muscular dystrophy drug received a a complete response letter from the FDA on Monday.  The Analysts Nomura Instinet analyst Christopher Marai maintained a Buy rating on Sarepta with a $230 price...

United Therapeutics Corporation (NASDAQ: UTHR)'s shares have shed more than 28% year-to-date, making its valuation attractive, according to Credit Suisse.  The Analyst Martin Auster upgraded United Therapeutics from Neutral to Outperform and raised the price target from $98 to $101. The...

Biogen Inc (NASDAQ: BIIB) to acquire gene therapy company Nightstar Therapeutics PLC (NASDAQ: NITE). Roche Holdings AG Basel ADR (OTC: RHHBY) agrees to buy Spark Therapeutics Inc (NASDAQ: ONCE). Sarepta Therapeutics Inc (NASDAQ: SRPT) exercises option to buy Myonexus Therapeutics for $165...

Roche Holdings AG Basel ADR (OTC: RHHBY)'s announcement regarding an agreement to acquire gene therapy company Spark Therapeutics Inc (NASDAQ: ONCE) has sparked a rally in the latter's shares. The Analysts Chardan analyst Gbola Amusa maintained a Neutral on Spark and lifted the...

The Street has a lot of faith in Sarepta Therapeutics, Inc. (NASDAQ: SRPT). The biotech firm notched its 20th bullish rating Thursday to further neutralize a lone Hold. The Rating Credit Suisse analysts Martin Auster, Mark Connolly and Tiago Fauth initiated coverage on Sarepta with an Outperform...

Insmed Incorporated (NASDAQ: INSM) announced in late March that it has submitted a new drug application to the FDA for a non-tuberculous mycobacterial lung disease treatment. The Analyst Credit Suisse analyst Martin Auster upgraded the shares of Insmed from Neutral to Outperform and...

Despite shares of United Therapeutics Corporation (NASDAQ: UTHR) being a consistent sell-side short amid mounting risks, a Credit Suisse analyst sees a buying opportunity. The Analyst Analyst Martin Auster upgraded shares of United Therapeutics from Neutral to Outperform and lowered the price...

Edge Therapeutics Inc (NASDAQ: EDGE) closed down 87 percent Wednesday and continued to decline Thursday after announcing layoffs, the discontinuation of its Phase 3 NEWTON 2 study and the evaluation of its next steps.  Even now, Credit Suisse considers Edge overvalued. The Rating Analyst...

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) have lost more than 10 percent over the past year, but one analyst is confident enough to call for upside to the stock. The Analyst Credit Suisse's Martin Auster initiated coverage of Alexion Pharmaceuticals' stock with an Outperform...

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced Tuesday that Paul Clancy has been appointed to replace Dave Anderson as CFO, effective July 31. Anderson will remain as a senior advisor through August to ensure a smooth transition. “Paul is well-known among biotech investors, having...

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) shares are down 23.5 percent in the past month as investors have grown concerned about the growth outlook for Solaris and the implications of the company's management shuffling. At this point, market pessimism has gotten so high that the absence of...